ADHD Drugs May Alleviate Menopausal Brain Fog
AIThis post was created with the assistance of artificial intelligence (AI).

TL;DR

A scoping review of five studies found that lisdexamfetamine and atomoxetine improved women’s self-rated executive function in small trials, but did not significantly improve objective cognitive test results. The findings are preliminary and do not establish either drug as a treatment for menopausal brain fog; larger independent studies are needed.

A scoping review presented at the Menopause Society annual meeting found that two ADHD medications improved women’s self-ratings of executive function in small trials, but did not significantly improve their results on objective cognitive tests. The findings suggest a possible avenue for research on menopausal brain fog, not an established treatment.

Before you orderOffer from Amazon

Get health and wellness essentials delivered free with Prime

  • Fast, free delivery on millions of items
  • Prime Video, Amazon Music and more included
  • Member-only deals all year
Start your free Prime trial Free trial for eligible customers · Cancel anytime
As an affiliate, we earn on qualifying purchases.

The review, led by Pallavi Khanna, MD, of the University of Tennessee Health Science Center, covered five studies. Three were randomized crossover trials involving 60 women without previous ADHD diagnoses; they examined lisdexamfetamine, sold as Vyvanse, and atomoxetine, sold as Strattera. In both sets of trials, participants reported less executive dysfunction while taking the medication than at baseline, with larger improvements than those reported during placebo periods.

On the Brown ADD Scales, where lower scores indicate less self-reported executive dysfunction, scores in the lisdexamfetamine study fell from 35.7 at baseline to 21.2 with the drug, compared with 29.8 with placebo (P<0.001). In the atomoxetine study, scores fell from 38.6 to 25.5 with the drug, compared with 30.1 with placebo (P=0.009). The researchers said neither medication significantly improved performance on the objective cognitive tests included in the trials.

The review also included two cross-sectional studies, covering 6,048 participants in Iceland and the United Kingdom, that looked at ADHD symptoms and menopause symptoms. In the Icelandic study, women with an ADHD diagnosis reported higher menopause symptom scores than women without one, and severe symptoms were more common. The U.K. study found that higher ADHD symptom scores, rather than diagnosis alone, were associated with worse menopause symptoms. These observational findings show an association; they cannot establish that ADHD symptoms cause more severe menopause symptoms.

At a glance
reportWhen: Presented October 22, 2026, at the Meno…
The developmentA review presented at the Menopause Society annual meeting found preliminary evidence that two ADHD drugs may improve women’s self-rated executive function during menopause, while objective test results did not show significant improvement.

Why Subjective Improvement Needs Testing

The results address a complaint that can affect daily life but has few specifically established treatment options. Khanna told MedPage Today that brain fog is a frequent concern in her menopause clinic and can resemble ADHD. The review suggests that women’s perceived difficulty with executive tasks may respond differently from performance measured by cognitive tests, a distinction that matters when judging whether a medication is helping.

For readers, the main implication is not that ADHD drugs should be used for menopause-related brain fog. The evidence is too limited to support that conclusion. Rather, the review identifies a question for larger trials: whether medication can produce reliable, meaningful benefits for menopausal cognitive symptoms, and for whom. The drugs also have not been compared with menopausal hormone therapy in the studies included, so this review does not show that one approach works better than another.

Products Worth Considering

Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor

Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor

As an affiliate, we earn on qualifying purchases.

How the Review Built Its Case

Khanna and colleagues searched five databases—Embase, PubMed, Scopus, PsycINFO and CENTRAL—for studies linking menopause with executive function, ADHD or ADHD medications. The three medication trials used a crossover design, in which participants received more than one study condition over time. Together, they enrolled 60 women and measured both self-reported executive function and performance on cognitive tests.

The two larger studies were observational rather than treatment trials. They used ADHD symptom measures and validated menopause scales in Icelandic and U.K. populations. In Iceland, women with ADHD had average menopause symptom scores of 18.0, compared with 13.0 among women without an ADHD diagnosis; severe symptoms were reported by 54.2% and 30.1%, respectively. Among women with more severe ADHD, the share reporting severe menopause symptoms was 72.8%, compared with 28.9% among those without ADHD. These figures describe those study groups and do not establish a general risk for every woman.

Khanna’s team proposed a biological rationale for studying the overlap: estradiol levels decline during the menopause transition, and dopamine and norepinephrine may also decline. ADHD involves related neurotransmitter systems. That rationale is a basis for investigation, not proof that the medications will relieve menopausal symptoms.

“Exciting and warrant testing in larger randomized trials.”

— JoAnn E. Manson, MD, MPH, DrPH, of Harvard Medical School, who was not involved in the study

Limits of the Early Evidence

The review is small, and its medication evidence has important limits. All three randomized trials came from one research group at a single institution, and they excluded women with diagnosed ADHD. The findings therefore do not establish how women with ADHD would respond, or whether results would hold in broader populations or independent trials.

The available studies also do not answer whether any self-reported improvement lasts, how large a change would be meaningful in everyday life, or how the drugs compare with menopausal hormone therapy. No included study examined methylphenidate, another commonly used ADHD medication. The review does not establish safety or support prescribing ADHD medications for menopausal brain fog; individual treatment decisions require a qualified clinician.

More broadly, the two population studies show associations between ADHD symptoms and menopause symptom burden, not evidence that one causes the other. The researchers said larger studies are needed to test the proposed link and determine whether ADHD symptom scores can help identify women who might benefit from further evaluation.

Larger Trials Are the Next Test

Khanna said larger, independent trials are needed. Future randomized studies could test whether the self-reported improvements are reproducible, examine objective cognitive outcomes alongside daily functioning, and include women with and without an ADHD diagnosis. A comparison with menopausal hormone therapy could help researchers understand how potential approaches differ, as Manson suggested.

No next trial, timeline or treatment recommendation was specified in the report. Until stronger evidence is available, the review should be read as an early research signal rather than a change in care. It remains unclear whether ADHD medications provide a clinically meaningful benefit for menopausal brain fog or which patients, if any, are most likely to benefit.

Key Questions

Did the review prove that ADHD drugs treat menopausal brain fog?

No. The review found improved self-rated executive function in small trials, but no significant improvement on objective cognitive tests. It does not establish these drugs as a treatment for menopausal brain fog.

Which medications were studied?

The three randomized crossover trials examined lisdexamfetamine (Vyvanse) and atomoxetine (Strattera). The review found no studies of methylphenidate (Ritalin).

How many people were included?

The three medication trials involved 60 women. Two additional cross-sectional studies from Iceland and the U.K. covered 6,048 participants and examined associations between ADHD symptoms and menopause symptoms.

Does having ADHD mean menopause symptoms will be worse?

The observational studies found an association between higher ADHD symptom levels and worse menopause symptom scores. They do not show that ADHD causes more severe menopause symptoms, and the findings do not predict an individual person’s experience.

What research is needed next?

The researchers called for larger, independent randomized trials. Studies could assess self-reported symptoms and objective cognitive outcomes, include women with diagnosed ADHD, and compare ADHD medications with menopausal hormone therapy.

Source: rss

This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare professional about your specific situation.
You May Also Like

Tenet Healthcare Surges In Global Coverage

Tenet Healthcare experiences a significant surge in international media mentions, signaling increased global interest in the company’s activities.

He Changed The World Of Organ Transplants. Would He Die Waiting For His Own?

A story titled ‘He Changed the World of Organ Transplants. Would He Die Waiting for His Own?’ is drawing reader and search interest. Details of the case remain unconfirmed.

Why Knowing Better Doesn’t Always Help You Change

A Tiny Buddha essay describes how a mother’s crisis prompted mindfulness, but insight alone did not undo her pattern of putting others first.

Friends Of BrainHealth Grants Advance Dementia Prevention And Brain Health Research

Friends of BrainHealth awarded six 2026 research grants and held a public vote for a seventh, supporting projects on dementia risk and brain health.